|
|
Volumn 249, Issue 5, 2011, Pages 631-632
|
|
Retreatment criteria in anti-VEGF therapy of exudative AMD: Critical analysis of present regimes and new morphological definition of "lesion activity"
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PEGAPTANIB;
RANIBIZUMAB;
VASCULOTROPIN INHIBITOR;
EDITORIAL;
ENDOPHTHALMITIS;
EUROPE;
EXUDATIVE MACULAR DEGENERATION;
EYE DISEASE;
HUMAN;
OPHTHALMOSCOPY;
OPTICAL COHERENCE TOMOGRAPHY;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
RECURRENT DISEASE;
RETINA FLUORESCEIN ANGIOGRAPHY;
RETINA MACULA AGE RELATED DEGENERATION;
RETINA MACULA EDEMA;
RETREATMENT;
RISK FACTOR;
TREATMENT DURATION;
VISUAL ACUITY;
VISUAL IMPAIRMENT;
ALGORITHMS;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
APTAMERS, NUCLEOTIDE;
DECISION TREES;
EUROPEAN UNION;
EXUDATES AND TRANSUDATES;
HUMANS;
MACULAR DEGENERATION;
PRACTICE GUIDELINES AS TOPIC;
RECURRENCE;
RETREATMENT;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
VISUAL ACUITY;
|
|
EID: 79955615679
PISSN: 0721832X
EISSN: None
Source Type: Journal
DOI: 10.1007/s00417-011-1639-3 Document Type: Editorial |
|
Times cited : (21)
|
|
References (4)
|
